Glycobond has developed HepaCheC™, an ELISA-based assay that detects aberrant and cancer-specific glycosylation on alpha-1 acid glycoprotein (AGP), an acute phase plasma protein produced mainly in the liver. The protein is secreted into the blood stream why analysis can be performed on a simple blood sample. The method is based on a patented fucose-binding protein, Mono-F, and has shown very promising results in longitudinal analyses of serum samples from patients at risk of developing HCC.

The Mono-F peptide was developed as a result of comprehensive binding studies of the lectin Aleuria Aurantia (1-3). Mono-F is a monovalent peptide with a high binding specificity for fucose, a carbohydrate epitope that is expressed at higher levels on AGP produced in liver cancer cells (4). 

 The assay will be considered as a complementary diagnostic method to the elevated AFP or other HCC diagnostic tests and will be clinically evaluated during 2017.

1. Olausson et al, Glycoconj J, 2008 Nov;25(8):753-62. 

2. Olausson et al, Glycobiology, 2011 Jan;21(1):34-44.

3. Bergström et al, J Chromatogr B Analyt Technol BiomedLife Sci, 2012 Feb 15;885-886:66-72.

4. Rydén et al, Clin Chem, 2002 Dec;48(12):2195-201.